autologous gene-modified PD-1-positive T lymphocytes Sc610

A preparation of autologous programmed cell death protein 1 (PD-1; PDCD1; CD279)-positive T lymphocytes transduced with a lentiviral vector encoding for an as of yet undisclosed receptor, with potential immunostimulatory and antineoplastic activities. Upon administration, autologous gene-modified PD-1-positive T lymphocytes Sc610 bind to tumor cells expressing the antigen for the as of yet undisclosed receptor, which may result in specific cytotoxic T-lymphocyte (CTL)-mediated tumor cell killing.